Table 2:
Colorectal cancer (CRC) detection within 2 years of a baseline fecal immunochemical test (FIT) at various positivity thresholds
| Overall cohort (n=640,859) | Threshold for test positivity | ||||
|---|---|---|---|---|---|
| 30 μg/g | 25 μg/g | 20 μg/ga | 15 μg/g | 10 μg/g | |
| Cancers detected | 822/1,245 | 867/1,245 | 925/1,245 | 950/1,245 | 987/1,245 |
| Programmatic sensitivityb (95% CI) | 66.0% (63.3–68.7) | 69.6% (67.0–72.2) | 74.3% (71.8–76.7) | 76.3% (73.8–78.6) | 79.3% (76.9–81.5) |
| Programmatic specificityc (95% CI) | 94.7% (94.6–94.7) | 93.8% (93.8–93.9) | 92.6% (92.5–92.6) | 90.8% (90.7–90.9) | 87.0% (86.9–87.1) |
| Positive FIT at baseline or within 2 yearsd | 35,017 (5.5%) | 40,399 (6.3%) | 48,561 (7.6%) | 59,869 (9.3%) | 84,293 (13.2%) |
| Positive results / 1 cancer detected (95% CI) | 43 (40–46) | 47 (44–50) | 52 (49–56) | 63 (59–67) | 85 (80–91) |
a
The current United States conventional FIT positivity threshold is 20 μg/g
b
Among those with colorectal cancer, the proportion with a positive FIT at baseline or within 2 years
c
Among those without cancer, the proportion without a positive FIT at baseline or within 2 years
d
Individuals with a positive result at baseline or within 2 years